Clinical Management
Clinical Management
HIV-Related Wasting Syndrome: Research
General
- Literature Citations for the Etiology of HIV-Associated Wasting (Regularly Updated)
From U.S. National Institutes of Health - Literature Citations for the Treatment of HIV-Associated Wasting (Regularly Updated)
From U.S. National Institutes of Health - Interventions for Fat Changes: New Research on Glitazones, Metformin and Testosterone (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Moderate Weight Loss Increasingly Common for HIVers on HAART (September 1, 2005)
Wasting syndrome may be on the decline, but moderate weight loss -- of 5% or more -- has increased steadily since 1995, and appears unrelated to lipodystrophy.
From aidsmap.com - Understanding the Role of HIV Load in Determining Weight Change in the Era of Highly Active Antiretroviral Therapy (January 2005)
Abstract of a study published in Clinical Infectious Diseases.
From International Association of Physicians in AIDS Care - Rosiglitazone Linked to Benign Tumors in Man With Lipodystrophy (August 17, 2004)
A case report ties the use of rosiglitazone, an experimental treatment for lipodystrophy-related fat loss, to the development of lipomas in one HIV-infected person.
From aidsmap.com - Rosiglitazone Reduces Lipoatrophy, Hyperinsulinemia in HIV-Infected Patients, Study Finds (May 19, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Predicting Lipoatrophy After Treatment Initiation (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Improvement in Lipoatrophy Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study (January 15, 2004)
When people who had developed lipoatrohpy while taking d4T (stavudine, Zerit) switched to abacavir (Ziagen) or AZT (zidovudine, Retrovir), their condition improved.
In Clinical Infectious Diseases - FRAM Study Finds a Lack of Association Between Lipoatrophy and Central Fat Gain (July 15, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Current Research on the Mechanisms Causing Lipoatrophy and Potential Treatments (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Rosiglitazone May Be Effective in Increasing Body Fat in Patients With Fat Wasting (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Substituting AZT or Abacavir for d4T in Patients With Lipoatrophy (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Thalidomide Pharmacokinetics, Safety and Effect on HIV Viral Load and Immune Parameters (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  |